Overview

The Therapeutic Goods Act 1989 was enacted to establish a national scheme for the regulation of therapeutic goods, aiming to ensure the safety, quality, and efficacy of these products in Australia. This Act addresses the gap in comprehensive regulation of therapeutic goods by providing a unified legal framework to govern their supply, importation, and advertising. The Act is administered by the Therapeutic Goods Administration (TGA), a division of the Australian Government Department of Health, with the policy objective of protecting public health by ensuring that therapeutic goods available in Australia are of acceptable quality and safety. The legislation allows the Secretary of the Department of Health to grant consents for the supply and importation of certain therapeutic goods that do not fully comply with the standards set out in therapeutic good orders, subject to specific conditions designed to protect public health. The Act empowers the Secretary to issue consents under specific sections, such as sections 14 and 14A, allowing for certain therapeutic goods to be supplied or imported despite not meeting all the regulatory standards, provided they meet the conditions stipulated in the consent. This mechanism facilitates the availability of therapeutic goods that may have minor non-compliances while still ensuring public health is safeguarded. The consents are granted for specified periods and are subject to review and renewal, ensuring ongoing compliance with public health standards. This legislative approach balances the need for regulatory flexibility with the paramount importance of public health protection.

Scope and Application

The Therapeutic Goods Act 1989 applies to the regulation of therapeutic goods within Australia, encompassing a wide range of products including medicines, medical devices, blood and blood components, tissues, and vaccines. The Act applies to all entities involved in the supply, importation, or exportation of these goods, ensuring that they meet the necessary safety, quality, and efficacy standards. The Act’s jurisdiction extends nationally across the Commonwealth of Australia, ensuring uniform standards and oversight of therapeutic goods. Certain exclusions and exemptions are outlined within the Act, including specific categories of goods that may be exempt from certain requirements under defined circumstances. The Act also provides for the issuance of consents, such as those granted to Bayer Australia Ltd for the supply of Elevit with Iodine, allowing for deviations from certain standards under specified conditions and for a defined period, as demonstrated by the consents given for the active ingredients content and disintegration times for this product. The application and enforcement of the Act can be further extended or restricted through subordinate instruments, which may include regulations and guidelines issued by the Therapeutic Goods Administration.

Key Provisions

Sections 14 and 14A of the Therapeutic Goods Act 1989 provide the legal framework for the consent of the Secretary of the Department of Health and Ageing to the supply and importation of therapeutic goods under specified conditions. The consent, granted between 10 November 2009 and 9 April 2010, pertains to Bayer Australia Ltd’s product, Elevit with Iodine, identified by its Australian Register of Therapeutic Goods number (ARTG No. 174543). This consent allows for the goods to be supplied and imported without full compliance with certain clauses of the applicable standards, as outlined in the Act. However, the consent is subject to specific conditions that must be met, such as limits on the content of active ingredients and maximum times for disintegration and dissolution tests. The obligations imposed by the Act on Bayer Australia Ltd and other parties include adhering to the specified conditions for the supply and importation of Elevit with Iodine. These conditions involve ensuring that the content of active ingredients like calcium, phosphorous, iodine, iron, magnesium, zinc, copper, folic acid, and manganese remains within prescribed limits. Additionally, the product must meet specific disintegration and dissolution times, with the option to modify the dissolution test method for folic acid under certain constraints. The consent also specifies the period for which it is valid, with some conditions applying indefinitely until further notice. Failure to comply with the conditions set out in the consent or the standards could result in serious legal consequences. While the Therapeutic Goods Act 1989 does not explicitly detail the penalties for non-compliance in this context, breaches of the Act generally attract significant fines and potential criminal charges. For instance, supplying therapeutic goods that do not meet the required standards can result in fines up to $330,000 for individuals and $1.65 million for corporations, along with imprisonment terms that can extend to several years. Therefore, it is crucial for the parties involved to strictly adhere to the stipulated conditions to avoid such severe repercussions.